Leap Therapeutics, Inc.

Biopharmaceutical companies have not taken a summer break from layoffs and are not waiting until later this month, when many will begin reporting second quarter earnings, to reveal their latest rounds

The capital markets continue to shy away from relatively risky investments, such as drug development, providing new funding for a limited number of companies. That means a lot of biopharmaceutical fir

The NASDAQ Biotech Index is down by nearly 27% since the last peak, the IPO window is virtually shut, there is diminished appetite for secondary offerings, the situation has been made worse by the col

While biopharma executives, investors and deal-makers are busy presenting at the J.P. Morgan Healthcare Conference in San Francisco, global political attention is fixating on a deal signed thousands o